Adverse effects leading to discontinuation of SJT/TEN therapy ‐ not reported · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Duration of ICU stay · Stevens‐Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Complete remission: all renal pathologies · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin may leads to higher complete remission: all renal pathologies compared with placebo or no treatment (low certainty).
1 finding from 1 review
Complete remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in complete remission: FSGS compared with placebo or no treatment (low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: complete remission (primary outcome… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Partial remission ( · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in treatment response at 52 weeks: partial remission (primary outcome 3) compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
Sustainable remission between 52 and 78 weeks: complete or partial remission (primary outcome 1, 2, 3) · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in sustainable remission between 52 and 78 weeks: complete or partial… compared with mycophenolate mofetil with pulse dexamethasone (moderate certainty).
1 finding from 1 review
CKD or death: death by 52 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: death by 52 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
CKD or death: 50% decline in GFR by 78 weeks · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in CKD or death: 50% decline in GFR by 78 weeks compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse effects (weeks 0 to 26): serious infection requiring hospitalisation · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): serious infection requiring… compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in adverse events (weeks 0 to 26): hypertension compared with mycophenolate mofetil with pulse dexamethasone (low certainty).
1 finding from 1 review
Complete or partial remission: all renal pathologies · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin may leads to higher complete or partial remission: all renal pathologies compared with placebo or no treatment (low certainty).
1 finding from 1 review
Complete or partial remission: FSGS · idiopathic steroid‐resistant nephrotic syndrome in children
Cyclosporin showed no clear difference in complete or partial remission: FSGS compared with placebo or no treatment (low certainty).
1 finding from 1 review
Adverse events: worsening of hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: worsening of hypertension compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: infection · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: infection compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: ESKD · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: ESKD compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Number with complete remission: complete remission in initial steroid resistance · idiopathic steroid‐resistant nephrotic syndrome in children
1 finding from 1 review
Number with complete remission: complete remission in delayed steroid resistance · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in delayed… compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Complete remission · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review
Adverse events: bronchospasm/treatment discontinued · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review